|
Dec 04 |
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Nov 28 |
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer...
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Nov 14 |
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update...
Announced 75% of ICI-naive patients alive at 36... |
|
Nov 09 |
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Ther...
75% of immune checkpoint inhibitor (ICI) naïve... |
|
Nov 07 |
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results...
PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Oct 23 |
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patien...
Combination of PDS0101 and KEYTRUDA® appears to... |
|
Oct 11 |
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Dr...
First study of patients with metastatic prostate cancer... |
|
Oct 03 |
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer P...
Interim VERSATILE-002 data for the first-line... |
|
Oct 02 |
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ct...
Study evaluated levels of circulating cell-free... |
|
Sep 26 |
PDS Biotech to Present at the LD Micro Main Event XVI...
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Sep 25 |
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic ...
Event to be held on Tuesday, October 3 from 8:00... |
|
Sep 20 |
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference...
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Sep 20 |
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies...
PDS0202 (Infectimune® + COBRA influenza... |
|
Sep 13 |
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-...
Company to provide updated VERSATILE-002 data on... |
|
Sep 06 |
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference...
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Sep 06 |
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference...
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 16 |
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer ...
Study evaluates the effect of combining PDS0101 with... |
|
Aug 14 |
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update...
Successful submission of final clinical protocol and... |
|
Aug 14 |
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial...
VERSATILE-003 will evaluate PDS0101 in... |
|
Aug 07 |
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results...
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 02 |
PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023...
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS... |
|
Jul 25 |
PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck ...
Data from ongoing VERSATILE-002 trial to... |
|
Jul 17 |
PDS Biotech Announces Acceptance of Abstract on Combination of PDS01ADC with Docetaxel in Metastatic Prostate Cancer for...
First clinical study of immunocytokine with... |
|
Jul 11 |
PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS01ADC...
Composition of matter and use patent for... |
|
Jun 30 |
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., June 30, 2023 (GLOBE... |
|
Jun 20 |
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023...
FLORHAM PARK, N.J., June 20, 2023 (GLOBE... |
|
Jun 14 |
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 a...
14 patients in the immune checkpoint inhibitor... |
|
Jun 05 |
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET...
FLORHAM PARK, N.J., June 05, 2023 (GLOBE... |
|
May 25 |
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA...
Interim data being presented at ASCO 2023 Annual... |
|
May 18 |
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Ad...
Company plans to initiate VERSATILE-003 Phase 3... |
|
May 15 |
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results...
Updated data from VERSATILE-002 Phase 2 trial to be... |
|
May 04 |
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results...
FLORHAM PARK, N.J., May 04, 2023 (GLOBE... |
|
Apr 27 |
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Com...
Abstract selected as featured poster to be... |
|
Apr 24 |
PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Deve...
FLORHAM PARK, N.J., April 24, 2023 (GLOBE... |
|
Apr 12 |
PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023...
FLORHAM PARK, N.J., April 12, 2023 (GLOBE... |
|
Apr 03 |
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week f...
PDS Biotech prepares to advance PDS0101 into a... |
|
Mar 30 |
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck ...
Company has completed Phase 3 manufacturing of... |
|
Mar 29 |
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium ...
FLORHAM PARK, N.J., March 29, 2023 (GLOBE... |
|
Mar 28 |
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results...
Successful meeting with FDA to discuss... |
|
Mar 16 |
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results...
FLORHAM PARK, N.J., March 16, 2023 (GLOBE... |
|
Mar 07 |
PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference...
FLORHAM PARK, N.J., March 07, 2023 (GLOBE... |
|
Mar 01 |
PDS Biotech Announces the Publication of PDS01ADC Study Linking Induced Changes in Immune Responses with Clinical Outcom...
National Cancer Institute (NCI)-led research of... |
|
Feb 27 |
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS01ADC and a Commercial Immune Ch...
Received guidance on registrational path for... |
|
Feb 16 |
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by ...
Infectimune™ (R-DOTAP) nanoparticles... |
|
Feb 08 |
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection...
Infectimune™ induced neutralizing antibody and... |
|
Feb 06 |
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress...
Abstract, titled “HPV16-specific CD4 and CD8 T... |
|
Jan 26 |
PDS Biotech Announces Participation in the Channelchek Takeaway Series...
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE... |
|
Jan 13 |
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference...
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE... |
|
Jan 03 |
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KG...
PDS Biotech bolsters immuno-oncology portfolio with a... |
